We see that a lot of telehealth platforms are beginning to pop up around the world and we can definitely tell you that this is a good thing that has been happening because of the fact that telehealth is much more convenient as compared to traditional visits to the clinic which cost you time, money as well as inconvenience. However, we are also seeing that there are a lot of telehealth platforms that are focusing on a single niche rather than trying to provide everything under one roof. One such telehealth platform is Allara which has just raised a Series A round of $10M in order to treat women with chronic hormonal conditions.
PCOS is one of the most common causes of female infertility, affecting as many as 5 million women, or 1 in 10, of reproductive age in the U.S., according to the CDC. Moreover, about 10% of women across the globe, which is equivalent to 176 million, have endometriosis. WHO says that “Despite how widespread these conditions are, patients with chronic hormonal disorders often undergo years of suffering before receiving treatment, and “up to 70% of cases are undiagnosed worldwide. “
Allara’s CEO Blank said, “I sought support from various doctors and specialists, did my own research, and played whack-a-mole with lifestyle changes, but wasn’t able to find effective and holistic care for my condition.” “There is no FDA-approved treatment for this widespread, chronic condition”. Allara hopes to change that with its comprehensive approach and care team that includes OB-GYNs, women’s health nurse practitioners, endocrinologists, and registered dietitians who deeply understand hormonal and metabolic care.
Allara informs us that “it has raised $10 million in a Series A round led by Google Ventures with participation from Great Oaks Venture Capital, Humbition, Vanterra, Gaingels and angel investors like One Medical founder Tom Lee and Maggie Sellers. Google Ventures’ general partner Frédérique Dame will join Allara’s board of directors. The new money brings its total capital raised to $17.5 million”. Allara’s CEO also mentions that since their inception, they have gone “from specialized PCOS care to comprehensive care services for women with hormonal, metabolic and gynecologic conditions,”